A few years ago, MedSIR organized a successful Think Tank event in Barcelona, Spain that revolved around the exciting new field of Immunotherapy in Cancer. Many young and established Medical Oncologists and scientists joined us for the two-day event which was highlighted by the presence of Prof. Antoni Ribas, one of the world’s leaders in the field.
Since then, MedSIR has designed a large variety of trials involving these new PD-1/PD-L1 agents and we are proud to finally begin our first trials in this domain.
The first one is the KELLY study, designed by Dr. Javier Cortés and colleagues, which will look at the efficacy and safety of the combination of MSD’s anti-PD-1 agent, pembrolizumab, and Eisai’s eribulin for the treatment of HR+/HER2- metastatic breast cancer. Recent results presented at the San Antonio Breast Cancer Symposium demonstrated very exciting efficacy of this combination in patients with mTNBC. Hopefully the KELLY study demonstrates similar benefit for patients.
The second immunotherapy-based trial that MedSIR will collaborate on together with study sponsor, Queen Mary University of London, is the ECLIPSE pre-operative study that will look to determine whether adding immune-modulatory agents to atezolizumab increases the probability of an immune response compared to atezolizumab alone in patients with operable ER+/HER2- breast cancer.
We are very excited to begin our first trials in the revolutionary and exciting field of Immunotherapy that we are just beginning to understand. Hopefully, many more trials will follow that will help patients as well as to help elucidate how to optimize treatment with these novel agents.
